MedPeerInc Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

MedPeerInc şirketinin toplam hissedar öz sermayesi ¥8.4B ve toplam borcu ¥3.4B olup, bu da borç-öz sermaye oranını 40.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥14.4B ve ¥6.0B dir. MedPeerInc 'in FAVÖK'ü ¥1.3B faiz karşılama oranı 101.8 dur. Şirketin ¥5.5B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

40.4%

Borç/özkaynak oranı

JP¥3.39b

Borç

Faiz karşılama oranı	101.8x
Nakit	JP¥5.45b
Eşitlik	JP¥8.40b
Toplam yükümlülükler	JP¥6.03b
Toplam varlıklar	JP¥14.42b

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

Nov 15

Recent updates

Need To Know: Analysts Just Made A Substantial Cut To Their MedPeer,Inc. (TSE:6095) Estimates

Nov 21

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

Nov 15

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Sep 04

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

Aug 02

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

May 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6095 'nin kısa vadeli varlıkları ( ¥8.9B ) kısa vadeli yükümlülüklerini ( ¥2.3B ) aşıyor.

Uzun Vadeli Yükümlülükler: 6095 şirketinin kısa vadeli varlıkları ( ¥8.9B ) uzun vadeli yükümlülüklerini ( ¥3.7B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6095 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 6095 şirketinin borç/öz sermaye oranı son 5 yılda 6.3% seviyesinden 40.4% seviyesine yükseldi.

Borç Kapsamı: 6095 'nin borcu işletme nakit akışı ( 37.8% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 6095 'in borcuna ilişkin faiz ödemeleri EBIT ( 101.8 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

MedPeerInc Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

Recent updates

Need To Know: Analysts Just Made A Substantial Cut To Their MedPeer,Inc. (TSE:6095) Estimates

Consensus revenue estimates fall by 18%

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

MedPeer,Inc., Annual General Meeting, Dec 18, 2024

New minor risk - Share price stability

Upcoming dividend of JP¥4.50 per share

Consensus EPS estimates increase by 31%

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Now 21% overvalued after recent price rise

MedPeer,Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Third quarter 2024 earnings released: EPS: JP¥10.59 (vs JP¥1.28 in 3Q 2023)

Investor sentiment deteriorates as stock falls 27%

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

MedPeer,Inc. to Report Q3, 2024 Results on Aug 14, 2024

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

Second quarter 2024 earnings released: JP¥4.15 loss per share (vs JP¥5.02 profit in 2Q 2023)

New minor risk - Market cap size

MedPeer,Inc. to Report Q2, 2024 Results on May 13, 2024

Consensus EPS estimates fall by 19%, revenue upgraded

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released: EPS: JP¥13.33 (vs JP¥12.40 in 1Q 2023)

New minor risk - Market cap size

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Q1, 2024 Results on Feb 13, 2024

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 9.1% to JP¥1,250

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Now 27% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Third quarter 2023 earnings released: EPS: JP¥1.28 (vs JP¥2.59 in 3Q 2022)

MedPeer,Inc. to Report Q3, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥5.02 (vs JP¥10.56 in 2Q 2022)

MedPeer,Inc. (TSE:6095) announces an Equity Buyback for 300,000 shares, representing 1.37% for ¥300 million.

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: EPS: JP¥12.40 (vs JP¥17.15 in 1Q 2022)

MedPeer,Inc. (TSE:6095) acquired Business support application series of recruit Medical Career.

Price target decreased to JP¥2,300

MedPeer,Inc. to Report Q1, 2023 Results on Feb 13, 2023

Now 20% undervalued

Now 23% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 19%

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

Price target decreased to JP¥2,600

MedPeer,Inc. (TSE:6095) completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.

MedPeer,Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 31%

Third quarter 2022 earnings released: EPS: JP¥2.59 (vs JP¥8.03 in 3Q 2021)

MedPeer,Inc. (TSE:6095) entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for ¥5000 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to JP¥3,580

Investor sentiment deteriorated over the past week

MedPeer,Inc. to Report Q3, 2022 Results on Aug 09, 2022

Price target decreased to JP¥4,276

MedPeer,Inc. (TSE:6095) acquired Minkore recently.

Price target decreased to JP¥4,496

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No independent directors

MedPeer,Inc. to Report Q2, 2022 Results on May 12, 2022

Now 23% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint